Elena Pezzolo
Vicenza, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 70 publications
Real-Life Effectiveness, Safety, and Growth Outcomes of Dupilumab in Children Aged 6 Months to 5 Years With Moderate-to-Severe Atopic Dermatitis: A Multicenter Retrospective Study from an Italian NPP Program.
Journal: Dermatitis : contact, atopic, occupational, drug
Published: May 07, 2026
Real-Life Effectiveness and Safety of Lebrikizumab in Elderly Patients with Atopic Dermatitis: A Multicenter Study.
Journal: Clinical and experimental dermatology
Published: April 12, 2026
Baricitinib versus ritlecitinib for severe alopecia areata: A 24-week real-world study.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: April 11, 2026
Longitudinal Response Trajectories with Dupilumab or Upadacitinib in Moderate-to-Severe Atopic Dermatitis: A Multicentre Real-World Study: IL-AD (Italian Landscape Atopic Dermatitis).
Journal: Dermatology and therapy
Published: March 17, 2026
Treatment Outcomes of Lebrikizumab after Switching from Dupilumab in Moderate-to-Severe Atopic Dermatitis involving the Head and Neck Area.
Journal: Dermatology and therapy
Published: March 11, 2026
Clinical and Functional Determinants of Caregiver Burden in Elderly Patients with Atopic Dermatitis: A Multicentre Cross-Sectional Study.
Journal: Clinical, cosmetic and investigational dermatology
Published: November 28, 2025
Efficacy and Safety of Abrocitinib for Moderate-to-severe Atopic Dermatitis in Adults: A 52-week Real-world Multicentre StudyIL-AD (Italian Landscape Atopic Dermatitis).
Journal: Acta dermato-venereologica
Published: November 16, 2025
Letter: Optimizing Dupilumab Dosing in Atopic Dermatitis: Real-World Evidence.
Journal: Dermatitis : contact, atopic, occupational, drug
Published: November 07, 2025
Ritlecitinib for Severe Alopecia Areata: A 24-Week, Multicentre, Real-World Study.
Journal: American journal of clinical dermatology
Published: November 05, 2025
Dupilumab for prurigo nodularis: real-world outcomes up to 104 weeks from the Dupilumab Italian Prurigo Nodularis (DUPItaPN) study.
Journal: Clinical and experimental dermatology
Published: October 21, 2025
Association of comorbidities and drug intake with generalized chronic pruritus: A multicenter case-control study in Switzerland and Italy.
Journal: JAAD international
Published: October 13, 2025
Effectiveness, Safety, and Health-Related Quality of Life in Moderate-to-Severe Atopic Dermatitis Treated with Lebrikizumab: A 16-Week Nationwide Retrospective Cohort Study.
Journal: Dermatology and therapy
Published: August 12, 2025
Last Updated: 09/26/2026